New Statesman / Pfizer Roundtables
The healthcare sector is undergoing significant change both in the UK and across the world, and the impacts resulting from these changes are far-reaching. Opening up dialogue and generating discussion amongst a wide-range of stakeholders is crucial to managing this process and building sustainable and successful reform for the future.
The New Statesman & Pfizer Policy Forum programme aims to encourage such a dialogue, bringing together leading opinion formers from across industry, government, regulators, think tanks, academics, professional, patient and consumer groups and the media to discuss the big issues facing the healthcare sector today.
Last event
World-class strategy for cancer
6 December 2007Participants in this recent Policy Forum discussion discussed the progress that may be expected on the newly released Cancer Reform Strategy and that of its predecessor, the 2000 Cancer Plan.
Participants in this recent Policy Forum discussion, a collaboration between the New Statesman and Pfizer, discussed the progress that may be expected on the newly released Cancer Reform Strategy and that of its predecessor, the 2000 Cancer Plan.
Between the publication of these two documents, many new drug therapies became available – expensive therapies that have led to disparities between primary care trusts about patients’ eligibility for them.
Next live event
Biotech Britain
24 April 2008From agriculture to antibodies, plastics to proteins, the economy of Britain in the 21st century is banking on biotech.
The unravelling of the human genome and the creation of crops that might help eradicate famine are just a few of the high profile breakthroughs that have promised a biotech revolution. The UK has been at the forefront of the science that has led to such promise, but also at the heart of a global debate that has often mischaracterised the nature of the biotech boom and, as a result, made the very word synonymous with controversy.
In this, the latest Pfizer/New Statesman Policy Forum, we explore the myth and reality of biotech, and examine the scientific, financial and political obstacles that stand in its way. We also question whether the UK will build upon the head start it’s had in the race to the top of the biotech league or whether our leading position is slipping away.
News
eGov monitor - A Policy Dialogue Platform - Health
05/09/2008Charity launches blog to bust cancer myths
05/09/2008
Extra Bluetongue Vaccine for Wales
05/09/2008
Heart and lung centre opens
Articles on Health
Is Labour abolishing illness?
01 May 2008
The new rules on incapacity benefit stake everything on a major gamble: that a large proportion of claimants are, in fact, well enough to work
[Read article]
- 37 comments
Can talking make you better?
01 May 2008
CBT does not cure cancer, schizophrenia or arthritis, but it does improve mood, coping and quality of life
[Read article]
- 20 comments
Don't lose your bottle
01 May 2008
Ignore the health fascists - drinking is a matter of personal choice
[Read article]
- 1 comment
A dangerous experiment
24 April 2008
This appalling documentary was exploitative and irresponsible
The Doctor Who Hears Voices Channel 4
[Read article]
- 10 comments
Your health
Fantasy Health Minister
Fantasy Health Minister, the game where you get the chance to shape health policy - but at what cost?
[Play Fantasy Health Minister]
Your comments
See what other New Statesman readers have had to contribute to the health forum
[Read comments]
